Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/0-306-46843-3_75 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rhabdomyolysis Following Trimethoprim-Sulfamethoxazole Therapy: A Case Report and Review of the Literature.
Curr Drug Saf
January 2025
National Center Chalbi Belkahia of Pharmacovigilance, Department of Collection and Analysis of Adverse Effects, Tunis, Tunisia, University of Tunis El Manar, Faculty of Medicine, Research unit: UR17ES12, Tunis, Tunisia.
Background: Trimethoprim-Sulfamethoxazole (TMP-SMX) is a commonly used antibiotic for the treatment of several infections, such as urinary tract infections, respiratory infections, and in certain cases, septic arthritis. Rhabdomyolysis (RM) is very rare and less than 20 cases have been reported, so far, in the literature, in particular in immunocompromised patients. Here, we report a case of TMP-SMX-induced RM in an immunocompetent patient, adding to the limited data on this association.
View Article and Find Full Text PDFEfficacy and safety of in patients with primary hyperoxaluria: A systematic review and meta-analysis of randomized controlled trials.
Indian J Urol
January 2025
Faculty of Medicine, Tanta University, Tanta, Egypt.
Background And Objective: Primary hyperoxaluria (PH), a rare autosomal recessive disorder, results in defective metabolism of oxalate, leading to increased oxalate levels. is a nonpathological anaerobic bacterium that uses oxalate for its survival and thus decreases the plasma oxalate levels. We aimed to use randomized controlled trials (RCTs) to evaluate the efficacy of in treating PH.
View Article and Find Full Text PDFEssential oils modulate virulence phenotypes in a multidrug-resistant pyomelanogenic Pseudomonas aeruginosa clinical isolate.
Sci Rep
January 2025
School of Biotechnology, Amrita Vishwa Vidyapeetham, Amritapuri, Kerala, India.
Pyomelanogenic P. aeruginosa, frequently isolated from patients with urinary tract infections and cystic fibrosis, possesses the ability to withstand oxidative stress, contributing to virulence and resulting in persistent infections. Whole genome sequence analysis of U804, a pyomelanogenic, multidrug-resistant, clinical isolate, demonstrates the mechanism underlying pyomelanin overproduction.
View Article and Find Full Text PDFProteomic insights into dual-species biofilm formation of E. coli and E. faecalis on urinary catheters.
Sci Rep
January 2025
Division of Microbiology, National Center for Toxicological Research, Food and Drug Administration (FDA), Jefferson, AR, U.S.A.
Infections associated with urinary catheters are often caused by biofilms composed of various bacterial species that form on the catheters' surfaces. In this study, we investigated the intricate interplay between Escherichia coli and Enterococcus faecalis during biofilm formation on urinary catheter segments using a dual-species culture model. We analyzed biofilm formation and global proteomic profiles to understand how these bacteria interact and adapt within a shared environment.
View Article and Find Full Text PDFMR-guided Transrectal Focal Laser Ablation for Localized Low- and Intermediate Risk Prostate Cancer: Initial Outcomes Using an Integrated Laser Ablation System.
J Vasc Interv Radiol
January 2025
Department of Medical Imaging, Radboud Institute for Health Sciences, Radboud University Medical Center, Geert Grooteplein 10, 6525 GA Nijmegen, The Netherlands.
Purpose: To investigate the feasibility and safety of MRI-guided focal laser ablation (FLA) in localized, International Society of Urological Pathology (ISUP) grade 1-3, prostate cancer (PCa) using an integrated system.
Methods: Ten consecutive males (mean age: 66±7 years) with low-to-intermediate risk PCa were prospectively included (April 2022-May 2023) and treated with MRI-guided FLA using an integrated system for laser energy control and MR thermometry monitoring. Primary endpoints were technical success, procedure-related adverse events (AEs) following SIR (Society of Interventional Radiology) classification, and 12-months local tumor progression-free survival (LTPFS), defined as no evident residual/ recurrent disease on follow-up imaging or histopathology at the treatment site.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!